New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation

Cardiovasc Res. 2021 Jun 16;117(7):1645-1661. doi: 10.1093/cvr/cvab080.

Abstract

Hormones are potent endo-, para-, and autocrine endogenous regulators of the function of multiple organs, including the heart. Endocrine dysfunction promotes a number of cardiovascular diseases, including atrial fibrillation (AF). While the heart is a target for endocrine regulation, it is also an active endocrine organ itself, secreting a number of important bioactive hormones that convey significant endocrine effects, but also through para-/autocrine actions, actively participate in cardiac self-regulation. The hormones regulating heart-function work in concert to support myocardial performance. AF is a serious clinical problem associated with increased morbidity and mortality, mainly due to stroke and heart failure. Current therapies for AF remain inadequate. AF is characterized by altered atrial function and structure, including electrical and profibrotic remodelling in the atria and ventricles, which facilitates AF progression and hampers its treatment. Although features of this remodelling are well-established and its mechanisms are partly understood, important pathways pertinent to AF arrhythmogenesis are still unidentified. The discovery of these missing pathways has the potential to lead to therapeutic breakthroughs. Endocrine dysfunction is well-recognized to lead to AF. In this review, we discuss endocrine and cardiocrine signalling systems that directly, or as a consequence of an underlying cardiac pathology, contribute to AF pathogenesis. More specifically, we consider the roles of products from the hypothalamic-pituitary axis, the adrenal glands, adipose tissue, the renin-angiotensin system, atrial cardiomyocytes, and the thyroid gland in controlling atrial electrical and structural properties. The influence of endocrine/paracrine dysfunction on AF risk and mechanisms is evaluated and discussed. We focus on the most recent findings and reflect on the potential of translating them into clinical application.

Keywords: Arrhythmia; Atrial fibrillation; Endocrine system; Heart.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenal Glands / metabolism
  • Adrenal Glands / physiopathology
  • Animals
  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / metabolism*
  • Atrial Fibrillation / physiopathology
  • Calcitonin / metabolism*
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / physiopathology
  • Endocrine System / drug effects
  • Endocrine System / metabolism*
  • Endocrine System / physiopathology
  • Heart Atria / drug effects
  • Heart Atria / metabolism*
  • Heart Atria / physiopathology
  • Humans
  • Hypothalamo-Hypophyseal System / metabolism
  • Hypothalamo-Hypophyseal System / physiopathology
  • Natriuretic Peptides / metabolism*
  • Obesity / epidemiology
  • Obesity / metabolism
  • Obesity / physiopathology
  • Renin-Angiotensin System*
  • Risk Factors
  • Signal Transduction
  • Thyroid Diseases / epidemiology
  • Thyroid Diseases / metabolism
  • Thyroid Diseases / physiopathology
  • Translational Research, Biomedical

Substances

  • Anti-Arrhythmia Agents
  • Natriuretic Peptides
  • Calcitonin